Roivant Sciences Ltd.
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $1.44M | $-0.26 | – |
| Q4 FY2025 Ended Mar 31, 2026 | May 20, 2026 | Before market open | $2.52M | $0.28 | – |
| Q3 FY2025 Ended Dec 31, 2025 | Feb 6, 2026 | Before market open | – | – | – |
| Q2 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $1.57M | $-0.17 | – |
| Q1 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | $2.17M | $-0.33 | – |
| Q4 FY2024 Ended Mar 31, 2025 | May 29, 2025 | Before market open | $7.57M | $-0.29 | – |
| Q3 FY2024 Ended Dec 31, 2024 | Feb 10, 2025 | Before market open | – | – | – |
| Q2 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Mar 31, 2024 | May 30, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Dec 31, 2023 | Feb 13, 2024 | Before market open | – | – | – |
Press releases
Announcements Roivant Sciences filed with the SEC
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with
Regulation FD disclosure · EX-99.1 to Form 8-K
LISRAYA (brepocitinib) Approved for Treatment of Patients with Dermatomyositis
Other events · EX-99.1 to Form 8-K
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Regulation FD disclosure · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
Regulation FD disclosure · EX-99.1 to Form 8-K
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Results of operations · EX-99.1 to Form 8-K
Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
Regulation FD disclosure · EX-99.1 to Form 8-K
December 11, 2025 New York City
Regulation FD disclosure · EX-99.2 to Form 8-K
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Brepocitinib in DM: VALOR Topline Results September 17, 2025
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutions for people with autoimmune
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business
Results of operations · EX-99.1 to Form 8-K
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and
Regulation FD disclosure · EX-99.1 to Form 8-K
Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutionsfor people with autoimmune disease MG &
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Regulation FD disclosure · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA ® (tapinarof) Cream, 1%
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Regulation FD disclosure · EX-99.1 to Form 8-K
September 2024 Dermavant Announces $1.2BN Deal with Organon
Regulation FD disclosure · EX-99.2 to Form 8-K
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble
Regulation FD disclosure · EX-99.1 to Form 8-K
High dose batoclimab achieved 76% response rate in patients uncontrolled on antithyroid drugs (ATDs) at week 12
Regulation FD disclosure · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion
Other events · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
Other events · EX-99.1 to Form 8-K
Targeted science, Tailored solutionsfor people with autoimmune
Other events · EX-99.2 to Form 8-K
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Other events · EX-99.1 to Form 8-K
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of
Material agreement · Other events · EX-99.1 to Form 8-K